A test in context: Critical evaluation of natriuretic peptide testing in heart failure

Journal of the American College of Cardiology

Volumn 67, Issue 3, 2016, Pages 330-337

  Francis, Gary S ^a   Felker, G Michael ^b   Tang, W H Wilson ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

biological markers; BNP; neprilysin; NT proBNP

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; MEMBRANE METALLOENDOPEPTIDASE; SACUBITRIL PLUS VALSARTAN; BIOLOGICAL MARKER; NATRIURETIC FACTOR;

BLOOD ANALYSIS; BLOOD VOLUME; CLINICAL FEATURE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DYSPNEA; ECHOCARDIOGRAPHY; HEART EJECTION FRACTION; HEART FAILURE; HEART HEMODYNAMICS; HUMAN; INDIVIDUALIZATION; KIDNEY FUNCTION; MEDICAL RESEARCH; OBESITY; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REVIEW; BLOOD; DISEASE MANAGEMENT; PATHOPHYSIOLOGY;

BIOMARKERS; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDES; PROGNOSIS;

EID: 84957827726     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.10.073     Document Type: Review

References (41)

1. J.C. Burnett Jr., P.C. Kao, D.C. Hu, and et al. Atrial natriuretic peptide elevation in congestive heart failure in the human Science 231 1986 1145 1147
2. A.J. de Bold, H.B. Borenstein, A.T. Veress, and et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats Life Sci 28 1981 89 94
3. J.C. Burnett Jr., J.P. Granger, and T.J. Opgenorth Effects of synthetic atrial natriuretic factor on renal function and renin release Am J Physiol 274 1984 F863 F866
4. R.W. Troughton, C.M. Frampton, T.G. Yandle, and et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations Lancet 355 2000 1126 1130
5. A.S. Maisel, P. Krishnaswamy, R.M. Nowak, and et al. Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure N Engl J Med 347 2002 161 167
6. J.L. Januzzi Jr., C.A. Camargo, S. Anwaruddin, and et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study Am J Cardiol 95 2005 948 954
7. J.D. Jamieson, and G.E. Palade Specific granules in atrial muscle cells J Cell Biol 23 1964 151 172
8. D.C. Lin, E.P. Diamandis, J.L. Januzzi Jr., and et al. Natriuretic peptides in heart failure Clin Chem 60 2014 1040 1046
9. G. Agnoletti, A. Rodella, R. Ferrari, and et al. Release of atrial natriuretic peptide-like immunoreactive material during stretching of the rat atrium in vitro J Mol Cell Cardiol 19 1987 217 220
10. P.T. Koller, R.J. Grekin, and J.M. Nicklas Paradoxical response of plasma atrial natriuretic hormone to pericardiocentesis in cardiac tamponade Am J Cardiol 59 1987 491 492
11. Y. Ogawa, K. Nakao, M. Mukoyama, and et al. Natriuretic peptides as cardiac hormones in normotensive and spontaneously hypertensive rats. The ventricle is a major site of synthesis and secretion of brain natriuretic peptide Circ Res 69 1991 491 500
12. S.R. Krim, R.P. Vivo, N.R. Krim, and et al. Racial/ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure J Am Coll Cardiol HF 1 2013 345 352
13. R.J. Rodeheffer, M. Naruse, J.B. Atkinson, and et al. Molecular forms of atrial natriuretic factor in normal and failing human myocardium Circulation 88 1993 364 371
14. T.J. Wang, M.G. Larson, D. Levy, and et al. Impact of obesity on plasma natriuretic peptide levels Circulation 109 2004 594 600
15. S.R. Das, M.H. Drazner, D.L. Dries, and et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study Circulation 112 2005 2163 2168
16. C.W. Yancy, M. Jessup, B. Bozkurt, and et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 1495 1539
17. J.J.V. McMurray, S. Adamopoulos, S.D. Anker, et al. ESC Committee for Practice Guidelines ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 Eur Heart J 33 2012 1787 1847
18. I.S. Anand, L.D. Fisher, Y.T. Chiang, et al. for the Val-HeFT Investigators Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT) Circulation 107 2003 1278 1283
19. I.S. Anand, T.S. Rector, J.G. Cleland, and et al. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial Circ Heart Fail 4 2011 569 577
20. G.C. Fonarow, W.F. Peacock, C.O. Phillips, et al. for the ADHERE Scientific Advisory Committee and Investigators Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure J Am Coll Cardiol 49 2007 1943 1950
21. S. Masson, R. Latini, I.S. Anand, et al. for the Val-HeFT Investigators Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial) J Am Coll Cardiol 52 2008 997 1003
22. P. Bettencourt, A. Azevedo, J. Pimenta, and et al. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients Circulation 110 2004 2168 2174
23. R.D. Kociol, J.R. Horton, G.C. Fonarow, and et al. Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims Circ Heart Fail 4 2011 628 636
24. R. Troughton, G.M. Felker, and J.L. Januzzi Jr. Natriuretic peptide-guided heart failure management Eur Heart J 35 2014 16 24
25. R.W. Troughton, C.M. Frampton, H.P. Brunner-La Rocca, and et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis Eur Heart J 35 2014 1559 1567
26. G.M. Felker, V. Hasselblad, A.F. Hernandez, and et al. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials Am Heart J 158 2009 422 430
27. G.M. Felker, T. Ahmad, K.J. Anstrom, and et al. Rationale and design of the GUIDE-IT study: Guiding Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure J Am Coll Cardiol HF 2 2014 457 465
28. M. Huelsmann, S. Neuhold, M. Resl, and et al. PONTIAC (NT-proBNP Selected PreventiOn of cardiac events in a population of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial J Am Coll Cardiol 62 2013 1365 1372
29. M. Ledwidge, J. Gallagher, C. Conlon, and et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial JAMA 310 2013 66 74
30. W.H. Tang, J.P. Girod, M.J. Lee, and et al. Plasma B-type natriuretic peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure Circulation 108 2003 2964 2966
31. G. Colbert, N. Jain, J.A. de Lemos, and et al. Utility of traditional circulating and imaging-based cardiac biomarkers in patients with predialysis CKD Clin J Am Soc Nephrol 10 2015 515 529
32. T. Breidthardt, S. Kalbermatter, T. Socrates, and et al. Increasing B-type natriuretic peptide levels predict mortality in unselected haemodialysis patients Eur J Heart Fail 13 2011 860 867
33. A. Luchner, G. Behrens, J. Stritzke, and et al. Long-term pattern of brain natriuretic peptide and N-terminal pro brain natriuretic peptide and its determinants in the general population: contribution of age, gender, and cardiac and extra-cardiac factors Eur J Heart Fail 15 2013 859 867
34. A.H. Wu Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results Am Heart J 152 2006 828 834
35. K.B. James, R.W. Troughton, J. Feldschuh, and et al. Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study Am Heart J 150 2005 984
36. M.E. Davis, A.M. Richards, M.G. Nicholls, and et al. Introduction of metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure Circulation 113 2006 977 985
37. R.P. Frantz, L.J. Olson, D. Grill, and et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure Am Heart J 149 2005 541 547
38. M. Packer, J.J.V. McMurray, A.S. Desai, et al. for the PARADIGM-HF Investigators and Coordinators Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure Circulation 131 2015 54 61
39. A.S. Jaffe, F.S. Apple, A. Mebazaa, and et al. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients Clin Chem 61 2015 1016 1018
40. S. Stienen, K. Salah, C. Dickhoff, and et al. N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements until a 30% reduction is attained during acute decompensated heart failure admissions and comparison with discharge NT-proBNP levels: implications for in-hospital guidance of treatment J Card Fail 21 2015 930 934
41. H.K. Gaggin, Q.A. Truong, S.U. Rehman, and et al. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study Congest Heart Fail 19 2013 135 142